Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16448959 | 0.93 | CXCR3 (0.87) | CXCR3KMT2ACSF1RACHEGSK3B | |
| SCHEMBL2223650 | 0.92 | CXCR3 (0.85) | CXCR3MEN1KMT2AACHEGSK3B | |
| SCHEMBL2267961 | 0.90 | CXCR3 (0.82) | CXCR3MEN1KMT2ACSF1RACHE | |
| SCHEMBL2221638 | 0.88 | CXCR3 (0.78) | CXCR3MEN1KMT2ACSF1RBRAF | |
| SCHEMBL2267498 | 0.84 | CXCR3 (0.72) | CXCR3MEN1KMT2AACHEGSK3B | |
| SCHEMBL12515722 | 0.84 | CXCR3 (0.72) | CXCR3MEN1KMT2AKCNMA1 | |
| SCHEMBL14669316 | 0.83 | CXCR3 (0.71) | CXCR3MEN1KMT2AACHEGSK3B | |
| SCHEMBL2269016 | 0.83 | CXCR3 (0.70) | CXCR3MEN1KMT2AKCNMA1 | |
| SCHEMBL2267308 | 0.82 | CXCR3 (0.70) | CXCR3MEN1KMT2A | |
| SCHEMBL2268257 | 0.82 | CXCR3 (0.70) | CXCR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | claimed |
| WO-2011084985-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | WO | claimed |
| US-11359011-B2 | Treatment and prevention of cardiovascular disease | Edifice Health, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210380672-A1 | Treatment and Prevention of Cardiovascular Disease | Edifice Health, Inc. (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210315921-A1 | Compounds and Methods for Modifying iAge | Edifice Health, Inc. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210040195-A1 | Treatment and Prevention of Cardiovascular Disease | Edifice Health, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
| US-8952004-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8952004-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8952004-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| WO-2011084985-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380672-A1 | Treatment and Prevention of Cardiovascular Disease | SERPINA6, FABP3, CXCL8 | CXCR3 835/4885MEN1 4411/4885KMT2A 2985/4885 |
| US-20210315921-A1 | Compounds and Methods for Modifying iAge | LIPG, IFNG, CD40LG | CXCR3 244/4885MEN1 2751/4885KMT2A 1498/4885 |
| US-20210040195-A1 | Treatment and Prevention of Cardiovascular Disease | SERPINA6, FABP3, CXCL8 | CXCR3 835/4885MEN1 4411/4885KMT2A 2985/4885 |
| US-11359011-B2 | Treatment and prevention of cardiovascular disease | SERPINA6, FABP3, CXCL8 | CXCR3 835/4885MEN1 4411/4885KMT2A 2985/4885 |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | CXCR3 1/4885MEN1 3640/4885KMT2A 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.